COVID-19 antibody / AvantGen, IGM Biosciences - LARVOL DELTA

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development (Businesswire) - "AvantGen, Inc....today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development....Under the licensing agreement, AvantGen grants IGM Biosciences the rights to convert the antibody clones into IgA or IgM format for further development for the treatment of COVID-19. AvantGen received an upfront payment from IGM Biosciences and is eligible to receive milestone and royalty payments."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease